ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy.
Saved in:
| Title: | ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy. |
|---|---|
| Authors: | Li Z; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Lv L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Yao X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Feng Z; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Xie Y; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China., Li K; Angel Pharmaceuticals Co. Ltd, Jiaxing, Zhejiang Province, China., Qi F; Beijing Imunopharm Technology Co. Ltd, Beijing, China., Yang M; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Wang J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China., Pan T; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China., Li X; Angel Pharmaceuticals Co. Ltd, Jiaxing, Zhejiang Province, China., Chen H; Angel Pharmaceuticals Co. Ltd, Jiaxing, Zhejiang Province, China., Wang J; Beijing Imunopharm Technology Co. Ltd, Beijing, China., Ding Y; Beijing Imunopharm Technology Co. Ltd, Beijing, China., Zhu J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China., Song Y; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China., Wang X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China. wangxiaomin@bjmu.edu.cn., Ding N; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Lymphoma Translational Research, Peking University Cancer Hospital & Institute, Beijing, China. ningding@bjmu.edu.cn. |
| Source: | Cell death discovery [Cell Death Discov] 2026 Mar 06; Vol. 12 (1). Date of Electronic Publication: 2026 Mar 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101665035 Publication Model: Electronic Cited Medium: Print ISSN: 2058-7716 (Print) Linking ISSN: 20587716 NLM ISO Abbreviation: Cell Death Discov Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
